* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Beijing Strong Biotechnologies's PEG Ratio or its related term are showing as below:
SZSE:300406'
s PEG Ratio Range Over the Past 10 Years
Min: 1.29 Med: 6.41 Max: 222.69
Current: 1.4
During the past 13 years, Beijing Strong Biotechnologies's highest PEG Ratio was 222.69. The lowest was 1.29. And the median was 6.41.
SZSE:300406's PEG Ratio is ranked better than 60.71% of 56
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.72
vs SZSE:300406: 1.40
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Beijing Strong Biotechnologies PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beijing Strong Biotechnologies's PEG Ratio
For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Strong Biotechnologies's PEG Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Strong Biotechnologies's PEG Ratio falls into.
Beijing Strong Biotechnologies PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Beijing Strong Biotechnologies (SZSE:300406) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Beijing Strong Biotechnologies PEG Ratio Related Terms
Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Beijing Strong Biotechnologies (SZSE:300406) Business Description
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300406 has been successfully added to your 